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Dear Editor, 
In chronic liver diseases, the management of patients 
must include a determination of the stage of fibrosis (to 
select specific therapies), a prognosis, the prevention of 
complications, and the surveillance of the disease. Over 
the  past  several  years,  significant  progress  has  been 
made in improving noninvasive methods of assessing 
liver fibrosis. The risks of liver biopsy and the potential 
for  sampling  errors  with  regard  to  fibrosis  staging 
support  the  use  of  noninvasive  modalities  including 
serum fibrosis markers or scores and elastography. The 
first are classified as direct (representing components of 
the extracellular matrix) or indirect (reflecting hepatic 
inflammation  and  function)  and  included  in  panels 
for  clinical  use.  They  include  patented  (i.e.  Fibrotest, 
Fibrometer) and nonpatented (ASL/ALT ratio, APRI, FIB-4, 
Forns, ELF, Hepascore) tests. The majority of studies has 
involved patients with chronic HCV infection. Direct and 
indirect methods have demonstrated good to excellent 
performance in detecting significant disease (≥ F2) and 
cirrhosis  (F4)  (1).  Transient  elastography  (Fibroscan®), 
which measures liver stiffness, has excellent accuracy in 
detecting cirrhosis (F4) in chronic liver diseases (2). The 
APRI (AST-to-platelet count ratio) is the most simple and 
cheapest indirect marker of inflammation and fibrosis 
(3).  Its  diagnostic  performance  in  detecting  advanced 
fibrosis has been evaluated extensively (4), showing low 
sensitivity  (41%),  low  negative  predictive  values  (64%), 
good specificity (95%) and high positive predictive values 
(88%).
In a study, a group of Turkish investigators presented 
their experience with the APRI in patients with chronic 
liver disease (5). In a retrospective series of 455 patients 
(207  with  HBV,  108  with  HCV,  and  140  with  NAFLD) 
the  low  value  (1)  median  Metavir  fibrosis  score  with 
median  values  for  APRI  were  reported  0.46,  0.49  and 
0.43  respectively  in  the  HBV,  HCV  and  NAFLD  groups. 
AUROC values for the detection of fibrosis (1 to 4) versus 
no fibrosis (F0) were 0.58, 0.54, and 0.62, respectively, in 
the 3 groups. Dr. Yilmaz and his team concluded that the 
APRI has acceptable accuracy in assessing liver fibrosis 
in patients with HCV and NAFLD but not in those with 
HBV. There are several drawbacks and flaws in this report 
that  render  its  message  unrealistic  and  erroneous.  It 
was  a  retrospective  series,  without  validation  in  an 
independent series, with 3 categories of etiologies, each Hepat Mon. 2011;11(7):565-566
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comprising a limited number of patients. It was not a 
consecutive  series,  and  the  indication  for  liver  biopsy 
was not mentioned, preventing the results from being 
applicable  to  other  clinicians  throughout  the  world. 
Furthermore, it is difficult to understand the basis for 
the diagnosis of NAFLD: US detection of steatosis ≥ 1 and 
absence of other causes of liver disease.
The main weaknesses of this study were that a poor 
marker  was  chosen  and  the  use  of  a  non-pertinent 
clinical  endpoint  (i.e.,  presence  or  of  fibrosis  not)  in 
place of significant fibrosis (≥ F2) and cirrhosis (≥ F4) or 
advanced (≥ F3) fibrosis. Thus, it is not surprising that the 
APRI performed poorly, with AUROCs largely inferior to 
the minimal value of 80%, well accepted by the medical 
community (6). Even Dr. Alberti’s group in Italy (7), which 
has great experience with the APRI, admits that this test 
alone has poor and variable performance, even in the 
identification of cirrhosis (AUROCs from 0.61 to 0.94 and 
0.69 to 0.88 for significant [i.e. ≥ F2] fibrosis) when used 
alone. They propose a model, called “Sequential Algorithm 
for Fibrosis Evaluation = safe biopsy algorithm,” in which 
APRI is used first, after which Fibrotest® is used as the 
second-line test in the setting of HCV and HBV, effecting 
47% and 82% spared liver biopsies in significant fibrosis 
and cirrhosis, respectively. Our group also has experience 
with the APRI, and we sought to compare, independently 
from  the  promoters,  its  diagnostic  accuracy  using 
AUROCs  for  the  prediction  of  significant,  advanced, 
and cirrhosis in HCV and other etiologies. Fibrotest was 
the most effective, followed by FIB-4, FORNS, APRI, and 
Fibroindex, in order of decreasing accuracy. In the global 
series and the HCV series, the AUROCs of the APRI were 
0.73  and  0.74  for  the  diagnosis  of  significant  fibrosis, 
reinforcing the observation that the minimal cut-off of 
80% was not reached.
In conclusion, the APRI alone is inappropriate for use in 
assessing liver fibrosis.
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